{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,8,20]],"date-time":"2023-08-20T02:39:05Z","timestamp":1692499145598},"reference-count":17,"publisher":"Japanese Society of Internal Medicine","issue":"20","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2021,10,15]]},"DOI":"10.2169\/internalmedicine.6979-20","type":"journal-article","created":{"date-parts":[[2021,4,25]],"date-time":"2021-04-25T22:07:15Z","timestamp":1619388435000},"page":"3305-3308","source":"Crossref","is-referenced-by-count":1,"title":["Early Transformation to Classic Hodgkin Lymphoma in a Chemotherapy-na\u00efve Chronic Lymphocytic Leukemia Patient upon Initial Treatment with Ibrutinib"],"prefix":"10.2169","volume":"60","author":[{"given":"Megumi","family":"Koshiishi","sequence":"first","affiliation":[{"name":"Department of Hematology\/Oncology, University of Yamanashi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toru","family":"Odate","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Yamanashi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukie","family":"Nakagawa","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, University of Yamanashi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, University of Yamanashi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuya","family":"Kumagai","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, University of Yamanashi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ichiro","family":"Kawashima","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, University of Yamanashi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeo","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, University of Yamanashi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kei","family":"Nakajima","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, University of Yamanashi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaru","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, University of Yamanashi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Oishi","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Yamanashi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetuso","family":"Kondo","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Yamanashi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keita","family":"Kirito","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, University of Yamanashi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 369: 32-42, 2013.","DOI":"10.1056\/NEJMoa1215637"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Burger JA, Tedeschi A, Barr PM, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med 373: 2425-2437, 2015.","DOI":"10.1056\/NEJMoa1509388"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Maddocks KJ, Ruppert AS, Lozanski G, et al. Etiology of ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia. JAMA Oncol 1: 80-87, 2015.","DOI":"10.1001\/jamaoncol.2014.218"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Iskierka-Ja\u017cd\u017cewska E, Pu\u0142a B, Szeremet A, et al. Ibrutinib discontinuation in patients with relapsed or refractory chronic lymphocytic leukemia treated in a compassionate use program: a report from the Polish Adult Leukemia Study Group (PALG). Adv Clin Exp Med 28: 1051-1057, 2019.","DOI":"10.17219\/acem\/99911"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Ahn IE, Underbayev C, Albitar A, et al. Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia. Blood 129: 1469-1479, 2017.","DOI":"10.1182\/blood-2016-06-719294"},{"key":"6","doi-asserted-by":"publisher","unstructured":"6. Hallek M, Cheson BD, Catovsky D, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood 131: 2745-2760, 2018.","DOI":"10.1182\/blood-2017-09-806398"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Khan M, Siddiqi R, Thompson PA. Approach to Richter transformation of chronic lymphocytic leukemia in the era of novel therapies. Ann Hematol 97: 1-15, 2018.","DOI":"10.1007\/s00277-017-3149-9"},{"key":"8","doi-asserted-by":"publisher","unstructured":"8. Tsimberidou AM, O'Brien S, Kantarjian HM, et al. Hodgkin transformation of chronic lymphocytic leukemia: the M. D. Anderson Cancer Center experience. Cancer 107: 1294-1302, 2006.","DOI":"10.1002\/cncr.22121"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Parikh SA, Habermann TM, Chaffee KG, et al. Hodgkin transformation of chronic lymphocytic leukemia: incidence, outcomes, and comparison to de novo Hodgkin lymphoma. Am J Hematol 90: 334-338, 2015.","DOI":"10.1002\/ajh.23939"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Bockorny B, Codreanu I, Dasanu CA. Hodgkin lymphoma as Richter transformation in chronic lymphocytic leukaemia: a retrospective analysis of world literature. Br J Haematol 156: 50-66, 2012.","DOI":"10.1111\/j.1365-2141.2011.08907.x"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Jamroziak K, Szymczyk A, Hus M, et al. Hodgkin's variant of Richter's transformation during ibrutinib therapy in a series of CLL patients; the Polish Adult Leukemia Group report (PALG). Eur J Haematol 100: 389-391, 2018.","DOI":"10.1111\/ejh.13016"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Quesada AE, Konoplev S. Classical Hodgkin lymphoma arising in a patient with chronic lymphocytic leukemia (Richter syndrome). Blood 130: 2151, 2017.","DOI":"10.1182\/blood-2017-07-794826"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Glavey S, Quinn J, McCloy M, et al. Emergence of Bruton's tyrosine kinase-negative Hodgkin lymphoma during ibrutinib treatment of chronic lymphocytic leukaemia. Eur J Haematol 99: 378-380, 2017.","DOI":"10.1111\/ejh.12911"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Sachanas S, Pangalis GA, Moschogiannis M, et al. Hodgkin lymphoma transformation of chronic lymphocytic leukemia under ibrutinib therapy: chance association or therapy-related? Anticancer Res 37: 3277-3280, 2017.","DOI":"10.21873\/anticanres.11692"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Taneja A, Jones J, Pittaluga S, et al. Richter transformation to Hodgkin lymphoma on Bruton's tyrosine kinase inhibitor therapy. Leuk Lymphoma 60: 519-522, 2019.","DOI":"10.1080\/10428194.2018.1480775"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Compagno M, Wang Q, Pighi C, et al. Phosphatidylinositol 3-kinase \u03b4 blockade increases genomic instability in B cells. Nature 542: 483-493, 2017.","DOI":"10.1038\/nature21406"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Bond DA, Huang Y, Fisher JL, et al. Second cancer incidence in CLL patients receiving BTK inhibitors. Leukemia 34: 3197-3205, 2020.","DOI":"10.1038\/s41375-020-0987-6"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/60\/20\/60_6979-20\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,16]],"date-time":"2021-10-16T05:57:47Z","timestamp":1634363867000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/60\/20\/60_6979-20\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,15]]},"references-count":17,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.6979-20","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,15]]},"article-number":"6979-20"}}